COVID-19 disease outcomes in patients receiving clozapine versus other antipsychotics: a national study in Qatar
Clozapine use was not associated with worse COVID-19 outcomes, supporting its relative safety during SARS-CoV-2 infection. These findings reassure clinicians regarding clozapine's continued use in treatment-resistant schizophrenia. However, the small clozapine sample size limits statistical power, warranting cautious interpretation and further research.
Authors
- Mohamed Ali Ahmed (ORCID: https://orcid.org/0000-0001-8911-735X)
- Ovais Wadoo (ORCID: https://orcid.org/0000-0001-5023-9245)
- Mohammed Faisal Hamad Mohammed
- Dalia Albahari (ORCID: https://orcid.org/0000-0003-1949-0102)
- Oraib Abdalla
- Shatha Alqam (ORCID: https://orcid.org/0009-0000-5418-9273)
Institutions
- Hamad Medical Corporation (QA)
- Qatar University (QA)
Publication Details
- Journal
- Frontiers in Psychiatry
- Published
- 2025-05-08
- DOI
- https://doi.org/10.3389/fpsyt.2025.1527378
- Citations
- 2
- Primary Topic
- Tryptophan and brain disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.16